Nanoparticle Technology for Immune Response Against Small and Macromolecules-Method of Preparation and Uses Thereof

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Researchers

Robert Langer / Elena Tonti / Jinjun Shi / Matteo Iannacone / Elliot Moseman / Ulrich Von Andrian / Pamela Basto / Frank Alexis / Omid Farokhzad

Departments: Office of the Institute Professors
Technology Areas: Chemicals & Materials: Polymers / Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living

  • immunonanotherapeutics that provide igg humoral response without t-cell antigen
    United States of America | Granted | 8,277,812
  • adjuvant incorporation in immunonanotherapeutics
    United States of America | Granted | 9,439,859
  • adjuvant incorporation in immunonanotherapeutics
    United States of America | Granted | 9,233,072
  • adjuvant incorporation in immunonanotherapeutics
    Russian Federation | Granted | 2,496,517
  • immunonanotherapeutics
    European Patent Convention | Granted | 2,344,186
  • adjuvant incorporation in immunonanotherapeutics
    United States of America | Granted | 8,637,028
  • adjuvant incorporation in immunonanotherapeutics
    China | Granted | 0
  • adjuvant incorporation in immunonanotherapeutics
    Israel | Granted | 212,240
  • immunonanotherapeutics that provide igg humoral response without t-cell antigen
    United States of America | Granted | 8,906,381
  • adjuvant incorporation in immunonanotherapeutics
    Korea (south) | Granted | 10
  • adjuvant incorporation in immunonanotherapeutics
    United States of America | Granted | 8,343,498

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies